ONCY News
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
December 9, 2020
ONCY News
Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting
November 9, 2020
ONCY News
Oncolytics Biotech Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche’s Anti-PD-L1 Checkpoint Inhibitor
October 27, 2020
ONCY News
Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
August 26, 2020
ONCY News
Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
June 25, 2020
ONCY News
Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
June 23, 2020
Featured News
ONCY News
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses with Systemic Pelareorep Treatment
June 4, 2020
ONCY News
Oncolytics Biotech® Announces Favorable AWARE-1 Safety Update
March 24, 2020
ONCY News
Oncolytics Biotech® Announces Statistically Significant Data Demonstrating the Potential of CEACAM6 as a Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
January 27, 2020
ONCY News
Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
January 22, 2020
1
2
Sign Up & Get FREE News Alerts From FNM Today!
Sign Up
